

If it would expedite the prosecution of this application, the Examiner is invited to confer with the Applicant's undersigned attorney.

Edward R. Gimmi
Attorney for Applicants
Registration No. 38,891

SMITHKLINE BEECHAM CORPORATION
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, PA 19406-0939
Phone (610) 270-4478
Facsimile (610) 270-5090
N:\ERG\APPS\micro\50052\USNational\prelimamend.DOC

Version with markings to Show Changes Made

1. (Amended) A method of determining the severity of Chronic Obstructive Pulmonary Disease (COPD) in a patient which comprises measuring the concentration of soluble E-cadherin in a sample of the patient's urine [and/]or blood serum and determining the extent of severity by reference to a correlation graph which correlates Forced Expiratory Volume in the first second of expiration (FEV1) with soluble E-cadherin concentration.
- 2 (Amended) A method of according to claim 1, wherein said[comprising] measuring step comprises measuring the concentration of soluble E-cadherin in a sample of the patient's blood serum.
- 3 (Amended) A method according to claim 1, wherein said[comprising] measuring step comprises measuring the concentration of soluble E-cadherin in a sample of the patient's urine.
4. (Amended) A method according to claims 1 [and/]or 2, wherein said[which comprises] measuring step comprises measuring the concentration of soluble E-cadherin in a sample of the patient's blood serum and urine.
6. (Amended) A method according to claim 5, wherein said[comprising] identifying step comprises identifying the concentration of soluble E-cadherin in a sample of the patient's blood serum.
7. (Amended) A method according to claim 5, wherein said[comprising] identifying step comprises identifying the concentration of soluble E-cadherin in a sample of the patient's urine.
8. (Amended) A method according to claim 5, wherein said[comprising] identifying step comprises identifying the levels of soluble E-cadherin in a sample of the patient's blood serum and urine.

Serial No.: To Be Assigned
Group Art Unit No.: Unknown

10. (Amended) A method according to claim 9, wherein said[comprising] monitoring step comprises monitoring the concentration of soluble E-cadherin in a sample of the patient's urine.

11. (Amended) A method according to claim 9, wherein said[comprising] monitoring step comprises monitoring the concentration of soluble E-cadherin in a sample of the patient's blood serum.

12. (Amended) A method according to claim 9, wherein said[comprising] monitoring step comprises monitoring the concentration of soluble E-cadherin in samples of the patient's urine and blood serum with time.

14. (Amended) A product according to claim 13, wherein said means to report the concentration of soluble E-cadherin comprises and anti-soluble E-cadherin antibody.

15. (Amended) A method according to [any one of claims 1 to 12]claim 1 wherein the correlation graph correlates FEV1 (as a percentage of the predicted value) with soluble E-cadherin concentration.